Study Conducted in Healthy Volunteers
Conditions
Brief summary
This is a Phase 1, single-center study to evaluate safety, tolerability, and bioavailability of subcutaneously administered lirentelimab (AK002) in adult healthy volunteers. Subjects will receive a single dose of intravenous AK002 or subcutaneous lirentelimab (AK002) assigned in a double-blind, randomized fashion.
Interventions
Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
OTHERPlacebo
Placebo
Sponsors
Allakos Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Subcutaneous cohorts will be assigned in a double-blind, randomized, placebo-controlled manner. IV cohorts will be open-label.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provided written informed consent. 2. Male or female aged ≥18 and ≤65 years at the time of signing the ICF. 3. Determined by the Investigator to be in good health as documented by medical history, vital signs, physical examination, laboratory assessments, ECG, and by general observations. 4. Subjects must weigh at least 50 kg and have a BMI between 18 g/m2 and 30 kg/m2, inclusive. 5. Negative urine drug screen at Screening. 6. Subjects must have the ability and willingness to attend the necessary visits to the study center and the ability to communicate effectively with the study site personnel. 7. Negative screening ova and parasite test. 8. Female subjects must be either post-menopausal for at least 1 year with FSH level \>40 IU/mL at Screening or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until the end of the study, or for 120 days following the last dose of study drug, whichever is longer. 9. Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from Screening until the end of the study or for 120 days following the last dose of study drug, whichever is longer. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.
Exclusion criteria
1. Peripheral blood absolute eosinophil count \>300/µL. 2. Known hypersensitivity to any constituent of the study drug. 3. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study. 4. Presence of abnormal laboratory values considered to be clinically significant by the Investigator. 5. Any disease of condition (medical or surgical) which, in the opinion of the Investigator, would place the subject at increased risk. 6. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer, or non-melanoma skin cancers. 7. Treatment with chemotherapy or radiotherapy in the preceding 6 months. 8. Treatment for a helminthic parasitic infection within 6 months of screening. 9. Use during the 30 days before Screening (or 5 half-lives, whichever is longer) or use during the Screening period of omalizumab, dupilumab, systemic immunosuppressive drugs, or systemic corticosteroids, except if receiving as part of a premedication protocol. 10. Vaccination with live attenuated vaccines within 30 days prior to initiation of treatment in the study, during the treatment period, or vaccination expected within 5 half-lives (4 months) of study drug administration. 11. Positive hepatitis serology results, except for vaccinated subjects or subjects with past but resolved hepatitis, at Screening. 12. Positive HIV serology results at Screening. 13. Alcohol, drug, or other substance abuse or dependence. 14. Any other reason that, in the opinion of the Investigator or Medical Monitor, makes the subject unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of lirentelimab (AK002) administered subcutaneously by evaluating adverse events assessed using the CTCAE version 5 | Day 0 (baseline) to Day 85 |
| Pharmacokinetics, including bioavailability, of lirentelimab (AK002) administered subcutaneously | Day 0 (baseline) to Day 85 |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacodynamics of lirentelimab (AK002) SC formulation as measured by changes in absolute peripheral blood counts of esoinophils | Day 0 (baseline) to Day 85 |
| Bioavailability of lirentelimab (AK002) SC formulation relative to lirentelimab (AK002) IV by analyzing the area under the serum AUC | Day 0 (baseline) to Day 85 |
Countries
United States
Outcome results
None listed